Synthesis of Potent Vanin-1 Inhibitors Labelled With Carbon-14 and Deuterium.

Bachir Latli, Matt Hrapchak, Ling Wu, Lalith Samankumara, Jaehee Lee, Bo Qu

Abstract read

In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bachir LatliThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.ORCID https://orcid.org/0000-0002-0024-9792

Matt HrapchakThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

Ling WuThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

Lalith SamankumaraThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

Jaehee LeeThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.ORCID https://orcid.org/0000-0003-2519-4828

Bo QuThe Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.ORCID https://orcid.org/0000-0001-7347-0108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanin-1 is an enzyme highly expressed in the kidneys, liver, and small intestines. Inhibition of this enzyme has been postulated as a novel approach in the treatment of several inflammatory diseases. BI 764122, BI 1585773, and BI 1595043 are very potent inhibitors of this enzyme. These three analogs share the same (S)-N-(nicotinoyl)pyrrolidin-3-yl)-N-methyl acetamide moiety. The preparation of these analogs labelled with carbon-14 was accomplished via carbon-14 carboxylation with carbon dioxide of corresponding aryl halides, followed by amide bond formation with (S)-N-(methyl)-N-(pyrrolidin-3-yl)acetamide. For metabolic considerations, the radioactive carbon was also incorporated in a cyclopropyl in [

Indexed as

Carbon RadioisotopesDeuteriumEnzyme InhibitorsN-Glycosyl HydrolasesChemistry Techniques, SyntheticIsotope LabelingCarbon-14Carbon RadioisotopesDeuteriumEnzyme InhibitorsN-Glycosyl HydrolasesBI 1585773BI 1595043BI 764122carbon‐14deuteriumvanin‐1

Identifiers

PMID42423615

DOI10.1002/jlcr.70033

PMCPMC13348488

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.